Julian Harrison

Stock Analyst at BTIG

(4.51)
# 198
Out of 5,441 analysts
56
Total ratings
Success rate
Average return
24 Stocks
Name Action PT Current % Upside Ratings Updated
TBPH Theravance Biopharma
Maintains: Strong Buy
24 25
11.4 119.3% 2 Jun 27, 2025
AVTX Avalo Therapeutics
Initiates Coverage On: Buy
40
8.92 348.43% 1 Dec 19, 2024
RNAC Cartesian Therapeuti...
Initiates Coverage On: Buy
42
11 281.82% 1 Dec 19, 2024
KROS Keros Therapeutics
Downgrades: Neutral
n/a
n/a n/a 3 Dec 12, 2024
ANAB AnaptysBio
Downgrades: Neutral
n/a
n/a n/a 2 Dec 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
50 9
1.96 359.18% 5 Nov 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
8
1.64 387.8% 4 Nov 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
8
n/a n/a 1 Nov 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
56 61
16.9 260.95% 3 Sep 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
13 15
5.93 152.95% 2 Sep 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
29 25
21.23 17.76% 3 Aug 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
41 51
53.77 -5.15% 2 Jul 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 4 Jun 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
43
69.02 -37.7% 1 May 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
32 40
15.22 162.81% 2 May 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 8 Feb 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
43
34.58 24.35% 1 Dec 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
4
3.35 19.4% 1 Nov 29, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Buy
150 150
1.6 9275% 1 Oct 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Sep 25, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
36
53.36 -32.53% 1 Mar 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
74 181
199.92 -9.46% 3 Dec 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
4
0.88 354.55% 1 May 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
n/a
n/a n/a 2 Feb 11, 2022